Sale

Lung Cancer Therapeutics Market

Global Lung Cancer Therapeutics Market Size, Share, Research: By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Metastatic Lung Cancer, Mesothelioma, Others; By Therapy: Chemotherapy, Others; By Therapy Type; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Lung Cancer Therapeutics Market Outlook

The global lung cancer therapeutics market size attained a value of USD 31.92 billion in 2023. The market is likely to grow at a CAGR of 11.60% during the forecast period of 2024-2032 to attain a value of USD 85.71 billion by 2032.

 

lung cancer therapeutics market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Lung Cancer Therapeutics Market Trends

Cancer refers to multiple tumours that can start developing in one of the body parts and spread uncontrollably to other parts of the body. Tumours are lumps of tissue which are often identified as the initial symptoms of cancer. In the later stages, when the cancerous cells spread abnormally to other organs, it becomes extremely difficult to treat them. This process is known as metastasis.

 

One of the primary causes of lung cancer is smoking. It can also happen due to using other types of tobacco and inhaling secondhand smoke or due to genetic factors.

 

Increasing Population of Smokers

The number of people smoking and adopting unhealthy lifestyles has become one of the major factors for the rising prevalence of lung cancer patients.

 

Development of Advanced Treatments

The development of advanced targeted treatments such as chemotherapy and radiation therapy. Moreover, with the FDA approving immunotherapy for lung cancer treatment, the market is likely to witness further growth in the forecast period.

 

Growing Focus on Research and Development

Companies have started to invest in research and development teams and collaborate with institutes to study and develop innovative treatment methods. This can further bolster the market growth in the coming years.

 

Increasing Investments by the Government

Governments of different countries have started investing in the infrastructural development of the healthcare sector and promoting treatment services. This can augment the market growth as the awareness among people rises.

 

Opportunities for the Global Lung Cancer Therapeutic Market

Implementation of Machine Learning

Companies have started to combine cancer treatment with machine learning. This will help the specialists identify cancer more efficiently with the CT scans.

 

Increasing Disposable Income

The rapid industrialisation in developing countries has propelled the disposable incomes of the population, which can augment the healthcare market and show positive opportunities for the expansion of lung cancer therapeutics.

 

Nanomedicine for Targeted Treatment

The development and implementation of nanomedicine can open up new opportunities for the market players and further propel the market development. This method of treatment will target the specific cancer cells for treatment and reduce the adverse effects of therapeutics.

 

Major Challenges for the Global Lung Cancer Therapeutic Market Development

Lack of Skilled Professionals

Cancer therapeutics and technologies require skilled and trained professionals for the proper management of the systems.

 

High Maintenance Costs for the Devices

The devices for cancer therapeutics require extensive amounts of money for maintenance and installation, which can be a hindering factor as smaller health institutions would avoid investing in these technologies.

 

Unequal Distribution of Cancer Care

Inadequate infrastructure and standardisation can hinder cancer care delivery, ultimately hindering the market growth.

 

Global Lung Cancer Therapeutics Market Analysis

 

lung cancer therapeutics market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on type, the market can be segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), among others. Based on the therapy, it can be bifurcated into chemotherapy, immunotherapy, radiation therapy, and targeted therapy, among others. Based on end-use, the market segments include hospitals, home care, and speciality clinics, among others. Based on distribution channels, the marker segments include hospital pharmacies, retail pharmacies, and online.

 

The regional markets for the lung therapeutics market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

 

The extensive E.M.R. report provides an in-depth evaluation of the market based on Porter's five forces model and a SWOT analysis

 

The lung cancer therapeutics market report comprehensively analyses key players in the market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments, and expansion plans.

 

  • Genentech, Inc.
  • AstraZeneca PLC
  • Novartis AG.
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim International GmbH
  • Others

 

Different Types of Lung Cancer

Based on type, the market segments include non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Non-small cell lung cancer develops at a slower rate than small-cell lung cancer. The cancer cells in this type are larger compared to the other type. It is the most common type of lung cancer, accounting for a major percentage of lung cancer cases.

 

Small-cell lung cancer spreads faster than non-small cell lung cancer and there are chances that this type of cancer can come back after treatment. This type of lung cancer is the least common type of lung cancer.

 

Different Therapies Available in the Market

Based on therapies, chemotherapy and radiation therapy hold a significant share of the market as they are the primary type of treatment given to patients. Chemotherapy is a type of cancer treatment conducted by using powerful drugs to kill fast-spreading cells or reduce the symptoms and prolong life.

 

Radiation therapy involves doses of radiation to kill cancer cells or slow down their growth by damaging their DNA. The treatment focuses on a particular body part where cancer cells are present.

 

Other treatments include immunotherapy and targeted therapy. Immunotherapy treatment utilises our body’s own immune system’s capabilities to control and treat cancer. It conditions our immune system to identify and attack cancer cells. It strengthens our immune system to fight against cancer cells if they return.

 

Targeted therapy as a type of cancer treatment utilises drugs to target the specific cells and proteins which help in the growth of cancer.

 

These Therapeutics Find End-Uses in Hospitals, Home Care, and Speciality Clinics

The lung cancer therapeutics market has several end-users including hospitals, homecare, and speciality clinics, among others. Among these segments, hospitals hold the largest share of the market.

 

With developing health infrastructure, larger hospitals are equipped with the latest technologies such as Gamma Cameras, PET/CT, CT simulation, and MRI (Magnetic Resonance Imaging), among others, for the diagnosis and treatment of cancer.

 

Cancer homecare is a specialised care service provided to patients as they deal with a lot of side effects. This service allows the patients to stay in a familiar environment with their families while receiving care from specialist.

 

Cancer speciality clinics are centres with specialised equipment and trained staff for the treatment of different types of cancer. Many developing countries are developing specialised clinics due to the increasing number of cases.

 

Distribution Channels include Hospital Pharmacies, Retail Pharmacies, and Online Channels

Based on distribution channels, the market segments include retail pharmacies, hospital pharmacies, and online pharmacies. Among these distribution channels, hospital pharmacy is expected to hold a significant share due to the increasing number of cases in hospitals.

 

Retail pharmacies are also growing in the market owing to the increasing preference of people to buy medicine from nearby stores. Online pharmacy is expected to hold a higher growth rate due to the rapid growth of the e-commerce industry.

 

lung cancer therapeutics market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

Genentech, Inc. is a biotechnology company based in the United States. They became a part of the Roche Group in March of 2009. They function independently within Roche.

 

They have been developing medicines for chronic and life-threatening diseases. Some of their major developments were treatment for locally advanced or metastatic non-small lung cancer and pancreatic cancer, and designed antibodies to stop the activation and reactivation of T-cells that cause psoriasis.

 

AstraZeneca PLC is a multinational company working in the field of pharmaceuticals and biotechnology, with a focus on developing and commercialising prescription medicines. Their areas for medicine development include Oncology, Cardiovascular and Metabolic Disease (CVMD) and Respiratory. They also collaborate with biotech research institutes to work with emerging technologies such as Modified RNA and CRISPR genome editing.

 

Novartis AG. is a Swiss multinational pharmaceutical company with a focus on creating treatments with science and technology in various sectors such as oncology, ophthalmology, neuroscience, and cardiovascular disorders, among many others. Novartis is also engaged in radioligand therapy, precision imaging, and gyroscope therapeutics.

 

Merck KGaA is a multinational company for science and technology with operations in different sectors such as healthcare, life science and electronics. They design and develop medicines and smart devices to treat diseases such as cancer and multiple sclerosis.

 

F. Hoffmann-La Roche Ltd is more commonly known as Roche. It is a multinational healthcare company based in Switzerland. They operate worldwide focusing on two sectors pharmaceuticals and diagnostics. They have started to focus on personalised healthcare with early detection of diseases and accurate diagnosis.

 

Boehringer Ingelheim International GmbH is a leading biopharmaceutical company, working with professionals on the latest innovation for the diagnosis of diseases for human health. The company works on drug discovery and development, and other healthcare products for heart diseases, metabolic diseases, cancer, lung diseases, mental disorders, and retinal diseases.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Cancer Type
  • Therapy
  • Therapy Type
  • End User
  • Distribution Channel
  • Region
Breakup by Cancer Type
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer (SCLC)
  • Metastatic Lung Cancer
  • Mesothelioma
  • Others
Breakup by Therapy
  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Others
Breakup by Therapy Type
  • Single Drug Therapy
  • Combination Therapy
Breakup by End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Genentech, Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim International GmbH
  • Agennix AG
  • Eli Lilly and Company
  • Sanofi-Aventis
  • GlaxoSmithKline
  • Hoffman-La Roche

 

Lung Cancer Therapeutics Market Report Snapshots

Lung Cancer Therapeutics Market Size

Lung Cancer Therapeutics Market Trends

Lung Cancer Therapeutics Companies

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions  
    1.3    Report Coverage – Key Segmentation and Scope
    1.4    Research Methodology
2    Executive Summary
3    Lung Cancer Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Lung Cancer Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Lung Cancer Epidemiology (2016-2031)
    5.3    Europe Lung Cancer Epidemiology (2016-2031)
    5.4    Asia-Pacific Lung Cancer Epidemiology (2016-2031)
    5.5    Latin America Lung Cancer Epidemiology (2016-2031)
    5.6    Middle East & Africa Lung Cancer Epidemiology (2016-2031)
6    Global Lung Cancer Therapeutics Market Overview 
    6.1    Global Lung Cancer Therapeutics Market Historical Value (2017-2023) 
    6.2    Global Lung Cancer Therapeutics Market Forecast Value (2024-2032)
7    Global Lung Cancer Therapeutics Market Landscape
    7.1    Global Lung Cancer Therapeutics Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global Lung Cancer Therapeutics Product Landscape
        7.2.1    Analysis by Cancer Type
        7.2.2    Analysis by Therapy
        7.2.3    Analysis by End User
8    Lung Cancer Therapeutics Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Lung Cancer Therapeutics Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model 
    10.4    Key Demand Indicators
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends 
    10.7    Value Chain Analysis
11    Global Lung Cancer Therapeutics Market Segmentation
    11.1    Global Lung Cancer Therapeutics Market by Cancer Type
        11.1.1    Market Overview 
        11.1.2    Non-Small Cell Lung Cancer
        11.1.3    Small Cell Lung Cancer (SCLC)
        11.1.4    Metastatic Lung Cancer
        11.1.5    Mesothelioma
        11.1.6    Others
    11.2    Global Lung Cancer Therapeutics Market by Therapy
        11.2.1    Market Overview
        11.2.2    Chemotherapy
        11.2.3    Immunotherapy
        11.2.4    Radiation Therapy
        11.2.5    Targeted Therapy
        11.2.6    Others
    11.3    Global Lung Cancer Therapeutics Market by Therapy Type
        11.3.1    Market Overview
        11.3.2    Single Drug Therapy
        11.3.3    Combination Therapy
    11.4    Global Lung Cancer Therapeutics Market by End User
        11.4.1    Market Overview
        11.4.2    Hospitals
        11.4.3    Homecare
        11.4.4    Specialty Clinics
        11.4.5    Others
    11.5    Global Lung Cancer Therapeutics Market by Distribution Channel
        11.5.1    Market Overview
        11.5.2    Hospital Pharmacy
        11.5.3    Retail Pharmacy
        11.5.4    Online Pharmacy
    11.6    Global Lung Cancer Therapeutics Market by Region
        11.6.1    Market Overview
        11.6.2    North America 
        11.6.3    Europe
        11.6.4    Asia Pacific
        11.6.5    Latin America
        11.6.6    Middle East and Africa
12    North America Lung Cancer Therapeutics Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Lung Cancer Therapeutics Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Lung Cancer Therapeutics Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Lung Cancer Therapeutics Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Lung Cancer Therapeutics Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Patent Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants Analysis
    18.1    Analysis by year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization
19    Clinical Trials Analysis 
    19.1     Analysis by Trial Registration Year 
    19.2    Analysis by Trial Status 
    19.3    Analysis by Trial Phase 
    19.4    Analysis by Therapeutic Area 
    19.5    Analysis by Geography  
20    Funding Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Regulatory Framework
    22.1    Regulatory Overview
        22.1.1    US FDA
        22.1.2    EU EMA
        22.1.3    INDIA CDSCO
        22.1.4    JAPAN PMDA
        22.1.5    Others
23    Supplier Landscape
    23.1    Genentech, Inc.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    AstraZeneca PLC
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Novartis AG
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Merck KGaA
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    F. Hoffmann-La Roche Ltd
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Boehringer Ingelheim International GmbH
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Agennix AG
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Eli Lilly and Company
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Sanofi-Aventis
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    GlaxoSmithKline
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Hoffman-La Roche
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
24    Global Lung Cancer Therapeutics Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The lung cancer therapeutics market was valued at USD 31.92 billion in 2023.

The market is expected to grow at a CAGR of 11.60% from 2024 to 2032 to reach a value of USD 85.71 billion by 2032.

The lung cancer therapeutics market is driven by the rising development of technology for treatment and diagnosis and an increasing number of cases due to the growth of the smoking population.

Governments are implementing plans to develop their healthcare infrastructure and organisations’ increasing focus on research and development to launch new and innovative treatment solutions are key trends in the market.

The regional markets for the global lung therapeutics market include North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

There are two main types of cancer available in the market for cancer therapeutics including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), among others.

The market segments for lung cancer therapeutics, based on therapy, include Chemotherapy, Immunotherapy, Radiation Therapy, and Targeted Therapy, among others.

These therapeutics find end-uses in hospitals, home care, and speciality clinics, among others.

The distribution channels in the market for lung cancer therapeutics include hospital pharmacies, retail pharmacies, and online.

If surgery is excluded from the options, combined chemotherapy and radiation therapy is the primary treatment used for lung cancer. For advanced lung cancers, radiation therapy can help in relieving pain and slowing down the advancement of cancer.

The United States Food and Drug Administration has approved Lumakras (sotorasib) for the treatment of non-small cell lung cancer in adult patients whose tumours have a specific genetic mutation known as KRAS G12C.

The key players in the market include Genentech, Inc., AstraZeneca PLC, Novartis AG., Merck KGaA, F. Hoffmann-La Roche Ltd, and Boehringer Ingelheim International GmbH, among others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER